MammaPrint Test May Help Decide Who Can Skip Chemotherapy

Source | Breastcancer.org

Published on CancerPort | 6 Sep 2016 | This extract has been reproduced on CancerPort as published on the Breastcancer.org's website and remains the property of the original source.

The MammaPrint test is a genomic test that analyzes the activity of a group of 70 genes from a breast cancer tissue sample that can affect how a cancer is likely to behave and respond to treatment. In the United States, MammaPrint can be used to analyze early-stage breast cancers that are:

  • stage I or stage II
  • invasive
  • smaller than 5 centimeters

In the rest of the world, MammaPrint can be used on cancers that are:

  • stage I or stage II
  • invasive
  • smaller than 5 centimeters
  • in three or fewer lymph nodes

In both the United States and internationally, MammaPrint can be used to analyze cancers that are hormone-receptor-positive and hormone-receptor-negative.

The MammaPrint test calculates whether the cancer has a low or high risk of coming back (recurring) within 10 years after diagnosis. Knowing if a cancer has a low or high risk of recurrence could help women and their doctors decide if chemotherapy or other treatments are needed after surgery -- called adjuvant treatments -- to reduce recurrence risk.

A study suggests the MammaPrint test can help decide which women can safely skip chemotherapy after surgery.

Click here to find out more about the MammaPrint test.
 

Reference: Breastcancer.org (25 Aug 2016) MammaPrint Test May Help Decide Who Can Skip Chemotherapy (Online) http://www.breastcancer.org/research-news/mammaprint-helps-decide-who-can-skip-chemo (Accessed 6 Sep 2016)

CancerPort Disclaimer: Practice, resources and drug availability mentioned or discussed on international websites may not be the same or available in South Africa. The views expressed on CancerPort are not meant to replace advice from your Doctor or Healthcare Practitioner. You should always seek medical advice before making any changes to your treatment or treatment plan.  This portal is intended to provide general information only. CancerPort has taken every precaution in compiling this portal, neither it, nor any contributor(s) to this site can be held responsible for any action (or the lack thereof) taken by any person or organisation wherever they shall be based, as a result, direct or otherwise, of information contained in, or accessed through, this website.

Rapid SSL Powered by LiveCAST, a VisualLive Solution
© Copyright 2019  I   Terms of Use   I   Disclaimer